SPRB

Spruce Biosciences, Inc.

Price Chart

Latest Quote

$52.36

+3.60 (+7.38%)

Current Price

Previous Close	$48.76
Open	$49.48
Day High	$52.72
Day Low	$49.48
Volume	138,720

Fetched: 2026-06-19T16:39:33

Stock Information

Shares Outstanding	2.75M
Total Debt	$7.12M
Cash Equivalents	$54.08M
Net Income	$-37.19M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$144.11M
EPS (TTM)	$-35.82
Exchange	NCM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$82.67M
Income	$-37.19M
Book/sh	$25.25
Cash/sh	$19.65
Employees	14

Financial Ratios

Quick Ratio	4.59
Current Ratio	4.67
Debt/Eq	20.55

Returns & Margins

ROA	-37.16%
ROE	-148.85%

Ownership

Insider Ownership	3.51%
Institutional Ownership	31.15%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	10.58
P/B	2.07

Analyst Data

Recommendation	strong_buy
Target Price	$149.71

Technical Indicators

SMA20	$50.14
SMA50	$55.22
SMA200	$71.68
RSI	52.00
ATR	3.8400

Shares Float	2.65M
Short Float	8.88%
Short Ratio	5.22
Volatility	3.20
Rel Volume	2.92

Performance History

Week	+6.63%
Month	+8.52%
Quarter	-11.32%
6 Months	-32.87%
YTD	-42.27%
Year	-87.25%
3 Years	-99.61%
5 Years	-99.92%
10 Years	-99.95%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-18	$52.36	171,000
2026-06-17	$48.76	73,400
2026-06-16	$47.10	61,600
2026-06-15	$49.90	69,000
2026-06-12	$51.89	80,900
2026-06-11	$49.10	69,400
2026-06-10	$47.13	34,000
2026-06-09	$49.03	42,600
2026-06-08	$49.32	31,100
2026-06-05	$50.43	33,900
2026-06-04	$53.17	67,500
2026-06-03	$49.05	65,300
2026-06-02	$49.30	32,900
2026-06-01	$50.70	31,200
2026-05-29	$51.27	54,300
2026-05-28	$49.19	50,100
2026-05-27	$49.52	29,900
2026-05-26	$51.81	50,400
2026-05-22	$51.08	71,400
2026-05-21	$52.70	51,600
2026-05-20	$51.51	60,000
2026-05-19	$48.25	90,200

About Spruce Biosciences, Inc.

Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, including anhedonia, weight alterations, and altered sleeping patterns. In addition, the company develops SPR202 for the treatment of Congenital Adrenal Hyperplasia (CAH), a chronic and potentially life-threatening rare disease with no cure. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize various pharmaceutical compounds. It also has a collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize Tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.

📰 Latest News

Here Are Tuesday’s Best Wall Street Analyst Research Calls: Dynatrace, Emerson Electric, Exxon Mobil, Flutter Entertainment, Genuine Parts, nVent Electric, Palantir Technologies, Roku, and More

24/7 Wall St. • 2026-06-16T11:52:27Z

Toll Brothers upgraded, Lennar downgraded: Wall Street's top analyst calls

The Fly • 2026-06-09T13:32:55Z

Wall Street Analysts Believe Spruce Biosciences (SPRB) Could Rally 181.21%: Here's is How to Trade

Zacks • 2026-04-03T13:55:01Z

Does Spruce Biosciences (SPRB) Have the Potential to Rally 208.32% as Wall Street Analysts Expect?

Zacks • 2026-03-18T13:55:03Z

Spruce Biosciences (SPRB) Appoints Dale Hooks as CCO and Reports Narrowed $39M 2025 Net Loss

Insider Monkey • 2026-03-17T23:59:43Z

Spruce Biosciences (SPRB) Gains FDA Support for Accelerated Approval Pathway

Insider Monkey • 2026-03-04T05:11:55Z

Spruce Biosciences Touts MPS IIIB Data, Targets Q4 BLA Submission at Oppenheimer Conference

MarketBeat • 2026-03-01T22:37:58Z

Spruce Biosciences initiated with an Outperform at Oppenheimer

TipRanks • 2025-12-24T11:30:37Z

Coty downgraded, Spruce Biosciences initiated: Wall Street's top analyst calls

The Fly • 2025-12-23T14:33:17Z

Here Are Tuesday’s Top Wall Street Analyst Research Calls: AMETEK, Coty, Janus Henderson, Levi Strauss, Pool Corporation, Southern Copper, and More

24/7 Wall St. • 2025-12-23T13:13:04Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$4,911,000	$10,089,000	$0
Operating Revenue	$0	$4,911,000	$10,089,000	$0
Expenses
Interest Expense	$90,000	$307,000	$483,000	$420,000
Total Expenses	$36,513,000	$61,062,000	$62,082,000	$47,283,000
Other Income Expense	$-3,500,000	-	-	-
Net Non Operating Interest Income Expense	$1,047,000	$3,115,000	$4,074,000	$1,103,000
Interest Expense Non Operating	$90,000	$307,000	$483,000	$420,000
Operating Expense	$36,513,000	$61,062,000	$62,082,000	$47,283,000
General And Administrative Expense	$16,991,000	$14,644,000	$12,650,000	$12,085,000
Other Non Operating Income Expenses	-	-	-	-
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-38,966,000	$-53,036,000	$-47,919,000	$-46,180,000
Net Interest Income	$1,047,000	$3,115,000	$4,074,000	$1,103,000
Interest Income	$1,137,000	$3,422,000	$4,557,000	$1,523,000
Normalized Income	$-35,466,000	$-53,036,000	$-47,919,000	$-46,180,000
Net Income From Continuing And Discontinued Operation	$-38,966,000	$-53,036,000	$-47,919,000	$-46,180,000
Total Operating Income As Reported	$-36,513,000	$-56,151,000	$-51,993,000	$-47,283,000
Net Income Common Stockholders	$-38,966,000	$-53,036,000	$-47,919,000	$-46,180,000
Net Income	$-38,966,000	$-53,036,000	$-47,919,000	$-46,180,000
Net Income Including Noncontrolling Interests	$-38,966,000	$-53,036,000	$-47,919,000	$-46,180,000
Net Income Continuous Operations	$-38,966,000	$-53,036,000	$-47,919,000	$-46,180,000
Pretax Income	$-38,966,000	$-53,036,000	$-47,919,000	$-46,180,000
Interest Income Non Operating	$1,137,000	$3,422,000	$4,557,000	$1,523,000
Operating Income	$-36,513,000	$-56,151,000	$-51,993,000	$-47,283,000
Per Share
Diluted EPS	$-50.83	$-96.40	$-93.00	$-147.00
Basic EPS	$-50.83	$-96.40	$-93.00	$-147.00
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-35,355,000	$-52,683,000	$-47,366,000	$-45,686,000
Total Unusual Items	$-3,500,000	-	-	-
Total Unusual Items Excluding Goodwill	$-3,500,000	-	-	-
Reconciled Depreciation	$21,000	$46,000	$70,000	$74,000
EBITDA (Bullshit earnings)	$-38,855,000	$-52,683,000	$-47,366,000	$-45,686,000
EBIT	$-38,876,000	$-52,729,000	$-47,436,000	$-45,760,000
Diluted Average Shares	$766,598	$550,146	$513,469	$313,694
Basic Average Shares	$766,598	$550,146	$513,469	$313,694
Diluted NI Availto Com Stockholders	$-38,966,000	$-53,036,000	$-47,919,000	$-46,180,000
Gain On Sale Of Security	$-3,500,000	-	-	-
Research And Development	$19,522,000	$46,418,000	$49,432,000	$35,198,000
Selling General And Administration	$16,991,000	$14,644,000	$12,650,000	$12,085,000
Other Gand A	$16,991,000	$14,644,000	$12,650,000	$12,085,000

Fetched: 2026-06-15

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$42,516,000	$28,821,000	$76,509,000	$68,486,000
Total Assets	$53,021,000	$45,209,000	$103,946,000	$85,648,000
Total Non Current Assets	$909,000	$1,003,000	$1,763,000	$2,040,000
Other Non Current Assets	$243,000	$69,000	$582,000	$640,000
Current Assets	$52,112,000	$44,206,000	$102,183,000	$83,608,000
Other Current Assets	$2,853,000	$2,276,000	$1,968,000	$1,211,000
Prepaid Assets	$353,000	$3,177,000	$3,876,000	$3,320,000
Cash Cash Equivalents And Short Term Investments	$48,906,000	$38,753,000	$96,339,000	$79,077,000
Cash And Cash Equivalents	$48,906,000	$38,753,000	$96,339,000	$24,487,000
Debt
Total Debt	$736,000	$2,765,000	$4,609,000	$6,315,000
Long Term Debt And Capital Lease Obligation	$419,000	$860,000	$2,736,000	$4,554,000
Current Debt And Capital Lease Obligation	$317,000	$1,905,000	$1,873,000	$1,761,000
Long Term Debt	-	$124,000	$1,717,000	$3,293,000
Current Debt	-	$1,622,000	$1,622,000	$1,622,000
Other Current Borrowings	-	$1,622,000	$1,622,000	$1,622,000
Liabilities
Total Liabilities Net Minority Interest	$10,505,000	$16,388,000	$27,437,000	$17,162,000
Total Non Current Liabilities Net Minority Interest	$419,000	$1,142,000	$2,972,000	$4,715,000
Current Liabilities	$10,086,000	$15,246,000	$24,465,000	$12,447,000
Payables And Accrued Expenses	$7,995,000	$12,459,000	$14,580,000	$9,400,000
Payables	$943,000	$1,295,000	$3,332,000	$1,426,000
Accounts Payable	$943,000	$1,295,000	$3,332,000	$1,426,000
Other Non Current Liabilities	-	$282,000	$236,000	$161,000
Current Deferred Liabilities	-	$0	$4,911,000	$0
Equity
Common Stock Equity	$42,516,000	$28,821,000	$76,509,000	$68,486,000
Total Equity Gross Minority Interest	$42,516,000	$28,821,000	$76,509,000	$68,486,000
Stockholders Equity	$42,516,000	$28,821,000	$76,509,000	$68,486,000
Retained Earnings	$-289,234,000	$-250,268,000	$-197,232,000	$-149,313,000
Gains Losses Not Affecting Retained Earnings	-	-	$0	$-558,000
Other Equity Adjustments	-	-	-	$-558,000
Other
Ordinary Shares Number	$1,372,043	$563,083	$547,064	$314,680
Share Issued	$1,372,043	$563,083	$547,064	$314,680
Tangible Book Value	$42,516,000	$28,821,000	$76,509,000	$68,486,000
Invested Capital	$42,516,000	$30,567,000	$79,848,000	$73,401,000
Working Capital	$42,026,000	$28,960,000	$77,718,000	$71,161,000
Capital Lease Obligations	$736,000	$1,019,000	$1,270,000	$1,400,000
Total Capitalization	$42,516,000	$28,945,000	$78,226,000	$71,779,000
Additional Paid In Capital	$331,750,000	$279,089,000	$273,737,000	$218,354,000
Capital Stock	$0	$0	$4,000	$3,000
Common Stock	$0	$0	$4,000	$3,000
Preferred Stock	$0	$0	$0	$0
Long Term Capital Lease Obligation	$419,000	$736,000	$1,019,000	$1,261,000
Current Capital Lease Obligation	$317,000	$283,000	$251,000	$139,000
Pensionand Other Post Retirement Benefit Plans Current	$1,774,000	$882,000	$3,101,000	$1,286,000
Current Accrued Expenses	$7,052,000	$11,164,000	$11,248,000	$7,974,000
Net PPE	$666,000	$934,000	$1,181,000	$1,400,000
Gross PPE	$666,000	$934,000	$1,181,000	$1,400,000
Other Properties	$666,000	$934,000	$1,181,000	$1,400,000
Current Deferred Revenue	-	$0	$4,911,000	$0
Other Short Term Investments	-	-	$0	$54,590,000
Investments And Advances	-	-	-	$0

Fetched: 2026-06-15

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-33,327,000	$-55,964,000	$-33,282,000	$-41,691,000
Operating Activities
Operating Cash Flow	$-33,327,000	$-55,964,000	$-33,275,000	$-41,683,000
Cash Flow From Continuing Operating Activities	$-33,327,000	$-55,964,000	$-33,275,000	$-41,683,000
Operating Gains Losses	$3,500,000	$2,000	$2,000	$39,000
Investing Activities
Investing Cash Flow	-	$0	$55,777,000	$23,692,000
Cash Flow From Continuing Investing Activities	-	$0	$55,777,000	$23,692,000
Capital Expenditure	-	-	$-7,000	$-8,000
Financing Activities
Issuance Of Capital Stock	$50,000,000	$0	$53,616,000	$0
Financing Cash Flow	$43,481,000	$-1,622,000	$49,140,000	$-241,000
Cash Flow From Continuing Financing Activities	$43,481,000	$-1,622,000	$49,140,000	$-241,000
Net Other Financing Charges	$-4,532,000	$-246,000	$-3,032,000	$-319,000
Net Common Stock Issuance	$50,000,000	$0	$53,616,000	$0
Common Stock Issuance	$50,000,000	$0	$53,616,000	$0
Net Preferred Stock Issuance	-	-	-	-
Preferred Stock Issuance	-	-	-	-
Other
Repayment Of Debt	$-2,057,000	$-1,622,000	$-1,622,000	$0
Interest Paid Supplemental Data	$68,000	$225,000	$369,000	$266,000
End Cash Position	$48,942,000	$38,788,000	$96,374,000	$24,732,000
Beginning Cash Position	$38,788,000	$96,374,000	$24,732,000	$42,964,000
Changes In Cash	$10,154,000	$-57,586,000	$71,642,000	$-18,232,000
Proceeds From Stock Option Exercised	$70,000	$246,000	$178,000	$78,000
Net Issuance Payments Of Debt	$-2,057,000	$-1,622,000	$-1,622,000	$0
Net Long Term Debt Issuance	$-2,057,000	$-1,622,000	$-1,622,000	$0
Long Term Debt Payments	$-2,057,000	$-1,622,000	$-1,622,000	$0
Change In Working Capital	$-724,000	$-8,571,000	$10,356,000	$1,132,000
Change In Other Current Liabilities	$-317,000	$-237,000	$-176,000	$-331,000
Change In Other Current Assets	$0	$494,000	$96,000	$90,000
Change In Payables And Accrued Expense	$-2,854,000	$-4,308,000	$8,161,000	$2,190,000
Change In Accrued Expense	$-2,502,000	$-2,271,000	$6,255,000	$3,587,000
Change In Payable	$-352,000	$-2,037,000	$1,906,000	$-1,397,000
Change In Account Payable	$-352,000	$-2,037,000	$1,906,000	$-1,397,000
Change In Prepaid Assets	$2,447,000	$391,000	$-2,636,000	$-817,000
Other Non Cash Items	$268,000	$247,000	$230,000	$-395,000
Stock Based Compensation	$2,574,000	$5,348,000	$4,622,000	$3,631,000
Depreciation Amortization Depletion	$21,000	$46,000	$70,000	$74,000
Depreciation And Amortization	$21,000	$46,000	$70,000	$74,000
Gain Loss On Investment Securities	$3,500,000	-	-	-
Gain Loss On Sale Of PPE	$0	$2,000	$2,000	$39,000
Net Income From Continuing Operations	$-38,966,000	$-53,036,000	$-47,919,000	$-46,180,000
Net Investment Purchase And Sale	-	$0	$55,784,000	$23,700,000
Sale Of Investment	-	$0	$67,665,000	$60,500,000
Purchase Of Investment	-	$0	$-11,881,000	$-36,800,000
Net PPE Purchase And Sale	-	$0	$-7,000	$-8,000
Purchase Of PPE	-	$0	$-7,000	$-8,000
Change In Other Working Capital	-	$-4,911,000	$4,911,000	-
Amortization Of Securities	-	$0	$-636,000	$16,000
Issuance Of Debt	-	-	-	$0
Long Term Debt Issuance	-	-	-	$0

Fetched: 2026-06-15